Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657087 | 1.00 | HSD11B1 (0.46) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4388248 | 0.93 | KDM5A (0.41) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4242122 | 0.93 | HCRTR2 (0.46) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4242113 | 0.93 | HCRTR2 (0.46) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL8226384 | 0.91 | HSD11B1 (0.46) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL8224313 | 0.87 | MGLL (0.42) | HSD11B1MGLL | |
| SCHEMBL4389150 | 0.86 | HCRTR1 (0.42) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4240919 | 0.85 | HSD11B1 (0.48) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4240915 | 0.85 | HSD11B1 (0.48) | HSD11B1MGLLKDM5AMCHR1HCRTR2 | |
| SCHEMBL4241791 | 0.84 | MGLL (0.50) | HSD11B1MGLLKDM5AMCHR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HSD11B1 164/4885MGLL 1527/4885KDM5A 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.